All In MedTech

Device Trial Radar · NCT07765862

A Prospective, Randomized, Two-Arm, Controlled, Single-Blind, Multi-Center Study to Evaluate the Safety and Efficacy of ArtiFix® Dural Repair Sealant Graft in Cranial and Spine Surgery (NEOFIX Study)

A PROSPECTIVE, RANDOMIZED, TWO-ARM, CONTROLLED, SINGLE-BLIND, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ARTIFIX® DURAL REPAIR SEALANT GRAFT IN CRANIAL AND SPINE SURGERY (NEOFIX STUDY)

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

228

Planned (sponsor's estimate)

Start

Jan 1, 2027

Primary completion

Jan 1, 2029

Study completion Jan 1, 2029

Sponsor

Lead sponsor
Nurami Medical LtdAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 14, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the NEOFIX study is to evaluate the safety and efficacy of ArtiFix® dural sealant graft in comparison to usual treatment for Dural repair (membrane that covers the brain and spinal cord) following cranial and spine surgeries. The investigated device will be implanted during the neurosurgical procedure and participants will be evaluated at 16, 36 and 120 days after the procedure.

Conditions

  • CerebroSpinal Fluid (CSF) Leak
  • Dural Tear

Interventions

  • ArtiFix® is a surgical dural sealant graft intended to close dural defects following cranial and spine surgeries.Device

    ArtiFix® is a sterile, synthetic, single use, adhesive, resorbable sealant graft intended to seal and repair dural defects following cranial or spinal surgeries.

  • Standard of Care (Investigator Choice)Device

    Standard-of-care for dural repair in spine or cranial procedures (only FDA cleared graft devices and approved sealants will be used)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The absence of device-related CSF leakage or re-operation of the implantation site within 120 days after implantation.Time frame: at 120 days after ArtiFix® or control implantation

1 more outcomes with a free account

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.